IGM Biosciences
Dr. Keyt has served as the Chief Scientific Officer since 2012, after serving in that role as a consultant beginning in 2010. Prior to joining IGM, Dr. Keyt served as Chief Technology Officer at Trellis Bioscience, an antibody discovery company, from 2007 to 2010. Previously, he served as Head of Research for Abmaxis, a biotechnology company, from 2005 through its acquisition by Merck in 2006. He was also Vice President of Preclinical Development at Abgenix, a biotechnology company, from 2001 through its acquisition by Amgen in 2005. Dr. Keyt was the Director of Pharmacology at Millennium Pharmaceuticals from 1998 to 2001. From 1982 to 1998, he served in various research and leadership roles at Roche/Genentech, where he made significant contributions to the discovery and development of Avastin, Lucentis, Activase tPA, TNKase-tPA and Kogenate (Factor VIII). Dr. Keyt received a B.A. in Chemistry from Washington University in St. Louis and a Ph.D. in Biochemistry and Pharmacology from Tufts University School of Medicine.
This person is not in any offices
IGM Biosciences
1 followers
IGM Biosciences (Nasdaq: IGMS) is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. IgM antibodies have inherent properties that we believe may enable them to improve upon the efficacy and safety of IgG antibodies in multiple therapeutic applications. We have created a proprietary IgM antibody technology platform that we believe is particularly well suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Our lead product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3, and we have initiated a Phase 1 clinical trial for the treatment of relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL) patients in 2019. Our second product candidate is IGM-8444, an IgM antibody targeting Death Receptor 5 (DR5) for the treatment of patients with solid and hematologic malignancies, for which we have recently initiated a Phase 1 clinical trial. Also in our product pipeline is IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.